School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Royalty Pharma PLC RPRX

Healthcare · Pharmaceuticals

$56.93last close 2026-10-09 · market cap $32.74B · delayed data

Trailing returns

1M-6.04%
3M-1.38%
6M+18.87%
1Y+60.58%
5Y+80.29%

Basis: Adjusted daily closes.

What it does

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.

Open RPRX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies